Ifinatamab deruxtecan
From Wikipedia, the free encyclopedia
 | |
| Clinical data | |
|---|---|
| Other names | DS-7300 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Daiichi Sankyo and Merck. It is an antibody–drug conjugate that "consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent".[1][2]
Ifinatamab-DXd is in phase III clinical trials for extensive stage small cell lung carcinoma (EC-SCLC) from 2024 onward.[3] I-DXd progressed directly from Phase I to Phase III, due to exceptional response rates (>65% ORR) in a difficult to treat cancer. I-DXd is also in Phase III trials for metastatic castration resistant prostate cancer from 2025[4]
